ArticleOncoTargets and therapy2018
High expression of USP22 predicts poor prognosis and advanced clinicopathological features in solid tumors: a meta-analysis.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Calpain Small Subunit 1 Protein in the Prognosis of Cancer Survivors and Its Clinicopathological Correlation.BioMed research international · 2019Pooled it
- Decoding the Oncogenic Role of USP22 Through Pan-Cancer Genomic and Epigenetic Analysis.Cancer reports (Hoboken, N.J.) · 2026Article
- M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression.Cancer research · 2022Article
- Clinicopathological and Prognostic Value of USP22 Expression in Gastric Cancer: A Systematic Review and Meta-Analysis and Database Validation.Frontiers in surgery · 2022Review
- The SAGA complex regulates early steps in transcription via its deubiquitylase module subunit USP22.The EMBO journal · 2021Article
- USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization.Oncology letters · 2021Article
- Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention.Cancers · 2021Review
- The POU2F1/miR-4490/USP22 axis regulates cell proliferation and metastasis in gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin.Oncology letters · 2020Article
- Targeting the SAGA and ATAC Transcriptional Coactivator Complexes in MYC-Driven Cancers.Cancer research · 2020Review
- USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression.Aging · 2020Article
- Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma.Digestive diseases and sciences · 2020Article
- USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks.Molecular cancer research : MCR · 2020Article
- Ubiquitin-specific peptide 22 acts as an oncogene in gastric cancer in a son of sevenless 1-dependent manner.Cancer cell international · 2020Article
- Ubiquitin-specific peptidase 22 promotes proliferation and metastasis in human colon cancer.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe expression of USP22 has been demonstrated to play a pivotal role in solid tumors. However, the prognostic value of USP22 still remains unknown. MATERIALS AND
methodsA systematic meta-analysis was performed to assess the prognostic value of USP22 in cancers. A literature collection was conducted from inception to June 8, 2017 by searching PubMed, Cochrane Library, Embase, Ovid and Web of Science databases. The pooled hazard ratio (HR) and odds ratio (OR) were used to correlate high expression of USP22 with overall survival (OS) and clinicopathological features.
resultsThe results, pooled by 19 studies with 2,876 cases, indicated that high expression of USP22 predicted poor OS (HR=2.48, 95% CI: 2.11-2.84,
conclusionOur finding revealed that USP22 might be an indicator of poor prognosis and advanced clinicopathological features of solid tumors and could be served as a novel biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.